"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Report Overview
2. Ankylosing Spondylitis (Bekhterev’s Disease)- Overview
3. Executive Summary
4. Ankylosing Spondylitis (Bekhterev’s Disease): Pipeline Assessment
4.1. By Stage of Development
4.2. By Route of Administration
4.3. By Drug Class
4.4. By Molecule Type
4.5. By Therapy Area / Indication
4.6. By Drug Target
4.7. By Sponsor
5. Ankylosing Spondylitis (Bekhterev’s Disease): Company & Drug Profiles
5.1. Clinical Stage
5.1.1. Fengshigutong – Sun Yat-sen University
5.1.1.1. Company Overview
5.1.1.2. Product Description
5.1.1.3. R&D Status & Development Activities
5.1.1.4. Mechanism of Action
5.1.1.5. Molecule Type
5.1.1.6. Stage of Development
5.1.1.7. Indications
5.1.1.8. Route of Administration
5.1.1.9. Funding
5.1.2. Bimekizumab – UCB Biopharma S.P.R.L.
5.1.2.1. Company Overview
5.1.2.2. Product Description
5.1.2.3. R&D Status & Development Activities
5.1.2.4. Mechanism of Action
5.1.2.5. Molecule Type
5.1.2.6. Stage of Development
5.1.2.7. Indications
5.1.2.8. Route of Administration
5.1.2.9. Funding
5.1.3. Tofacitinib – Pfizer
5.1.3.1. Company Overview
5.1.3.2. Product Description
5.1.3.3. R&D Status & Development Activities
5.1.3.4. Mechanism of Action
5.1.3.5. Molecule Type
5.1.3.6. Stage of Development
5.1.3.7. Indications
5.1.3.8. Route of Administration
5.1.3.9. Funding
5.1.4. Others
5.2. Preclinical
5.2.1. Company Overview
5.2.2. Product Description
5.2.3. R&D Status & Development Activities
5.2.4. Mechanism of Action
5.2.5. Molecule Type
5.2.6. Indications
5.2.7. Route of Administration
5.2.8. Funding
6. Ankylosing Spondylitis (Bekhterev’s Disease): An Overview on Dormant & Discontinued Pipeline Candidates
6.1. Overview
6.2. Product Description
6.3. Reason for Discontinuation
7. Ankylosing Spondylitis (Bekhterev’s Disease): Additional Key Insights
7.1. Epidemiology Overview: Ankylosing Spondylitis (Bekhterev’s Disease)
7.2. Current Market Scenario: Ankylosing Spondylitis (Bekhterev’s Disease) Therapeutics
8. Ankylosing Spondylitis (Bekhterev’s Disease): News, Press Releases and Conference Details
Note:
1) This Table of Content is tentative and subject to change as the research progresses.
2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.